Hunter Fleming Ltd (Aegis)

Aegis Pharmaceuticals Ltd was a University of Bristol spin out company set up in December 1999 to develop novel pharmaceutical products for the treatment of immunological and infectious disease.  Drug discovery company Hunter-Fleming acquired Aegis and merged the company into Hunter-Fleming at the beginning of 2001.  The Aegis technology is based on the development of a bacterial protein for correcting disorders of the immune system such as diabetes, rheumatoid arthritis and allergic rhinitis; and for improving the effectiveness of vaccines used to combat bacterial and viral infections.  Hunter-Fleming has recently completed a £15.5 million funding round for continued development of its portfolio of technologies.  This exercise also involved the formulation of new company Trident Pharmaceuticals plc.

Contact: Dr Jim Murray